Get the Stockscreener App
5.88
3.13%
-0.19
After Hours:
5.61
-0.27
-4.59%
Emergent Biosolutions Inc stock is traded at $5.88, with a volume of 1.32M.
It is down -3.13% in the last 24 hours and down -7.84% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$6.07
Open:
$6.07
24h Volume:
1.32M
Relative Volume:
1.06
Market Cap:
$319.15M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.3984
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
-21.29%
1M Performance:
-7.84%
6M Performance:
-47.73%
1Y Performance:
-53.74%
1-Day Range:
$5.85
$6.07
1-Week Range:
$5.85
$7.53
52-Week Range:
$4.02
$13.28
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
5.88 | 329.47M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
What catalysts could drive Emergent BioSolutions Inc. stock higher in 2025Chart Pattern Ideas For Fast Growth - jammulinksnews.com
What institutional investors are buying Emergent BioSolutions Inc. stockPost Market Outlook For Every Investor - jammulinksnews.com
Why Emergent BioSolutions Inc. stock attracts strong analyst attentionValue Investing Picks With Stability Outlined - beatles.ru
Emergent BioSolutions Inc. Recovery Hinges on Volume BreakoutPotential Breakout Stock List Published This Week - metal.it
Investors Hope for Bounce in Emergent BioSolutions Inc. After SelloffAI Based High Gain Watchlist Scanner Shared - metal.it
Can Emergent BioSolutions Inc. Regain Momentum After BreakdownCapital Growth With Controlled Risk Picks Suggested - metal.it
Published on: 2025-07-29 03:10:46 - metal.it
Emergent BioSolutions (EBS) Applauds Naloxone Accessibility in U - GuruFocus
Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives - The Manila Times
Emergent BioSolutions Publishes Review on Brincidofovir for Mpox Treatment in Expert Review of Anti-infective Therapy - Quiver Quantitative
Is Emergent BioSolutions Inc. stock overvalued or undervaluedHigh-performance stocks for savvy investors - jammulinksnews.com
U.S. House Takes Historic Step: NARCAN Now Available in Every Building to Prevent Opioid Deaths - Stock Titan
What are analysts’ price targets for Emergent BioSolutions Inc. in the next 12 monthsFree Stock Selection - jammulinksnews.com
How many analysts rate Emergent BioSolutions Inc. as a “Buy”Invest smarter with advanced market data - jammulinksnews.com
Published on: 2025-07-28 04:58:37 - jammulinksnews.com
How volatile is Emergent BioSolutions Inc. stock compared to the marketRecord-breaking gains - jammulinksnews.com
Is it the right time to buy Emergent BioSolutions Inc. stockInvest confidently with actionable market data - jammulinksnews.com
How strong is Emergent BioSolutions Inc. company’s balance sheetMaximize returns with strategic stock selection - jammulinksnews.com
What drives Emergent BioSolutions Inc. stock priceTriple-digit profit margins - PrintWeekIndia
What analysts say about Emergent BioSolutions Inc. stockExponential wealth increase - PrintWeekIndia
Is Emergent BioSolutions Inc. a good long term investmentHigh-yield growth strategies - PrintWeekIndia
Emergent BioSolutions Inc. Stock Analysis and ForecastExplosive wealth accumulation - jammulinksnews.com
Is MDU Resources Group Inc. a good long term investmentHigh-yield investments - jammulinksnews.com
AGYS Stock Analysis and ForecastAccelerated financial growth - Autocar Professional
Hawthorn Bancshares Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):